Efficacy and safety of Lianhuaqingwen capsules in high-risk common type COVID-19 pneumonia:A multicenter retrospective study

Objective:To evaluate the clinical safety and efficacy of Lianhuaqingwen(LHQW)capsules in patients with high-risk common type COVID-19 pneumonia.Methods:A retrospective multicenter study on 383 high-risk common type COVID-19 pneumonia cases was conducted.Patients were categorized as the standard treatment(SDT)group(n=168)and the LHQW+SDT group(n=215).The primary endpoint was the rate of symptom(fever,fatigue,coughing)recovery and the secondary endpoints included the time to symptom recovery,the proportion of patients with improvement in chest CT images,the proportion of patients with clinical cure,the timing and rate of negative conversion of SARS-CoV-2 RNA assay.Results:The recovery rate was significantly higher in the LHQW+SDT group as compared with the SDT group(89.7%vs.72.0%,P<0.01).The combined use of LHQW+SDT also showed shorter time for symptom recovery,as well as shorter time for individual symptom of fever,fatigue and coughing recovery than use of SDT alone.A higher proportion of patients in the LHQW+SDT group with improvements in chest CT images and clinical cure(77.7%vs.57.1%,P<0.01)but the proportion of patients deteriorating to severe cases(1%vs.25%,P<0.01)in this group was significant lower than those in the SDT group.No significant difference in negative conversion rate of viral assay results was observed(76.8%vs.75.0%,P>0.05).No serious adverse events were reported.Conclusions:LHQW capsules could be recommended to ameliorate clinical symptoms and reduce the rate of deteriorating to severe cases for high-risk common type COVID-19 pneumonia.

Progress in frailty assessment in the treatment of patients with chronic obstructive pulmonary disease

This paper reviews the asthenia´s occurrence status,adverse outcomes and assessment tools of patients with chronic obstructive pulmonary disease,as well as safety management strategies such as preventing or improving pulmonary rehabilitation and nutritional therapy in patients with asthenia´s.It can provide reference for clinical nurses or researchers to find or develop assessment tool asthenia suitable for domestic patients with chronic obstructive pulmonary disease and set down intervention measurements.

Nursing and change: Is it time to revisit empowerment?

International Nurses’Day is an annual milestone;a reminder that nurses and nursing are found across the globe,in diverse populations,diverse societies and health care settings.International Nurses’Day seeks to illuminate the complexities of nursing,and is usually celebrated on 12th May,in commemoration of Florence Nightingale’s birthday.This year’s theme is‘Nurses:A Force for Change e A vital resource for health’.The theme could not be more appropriate.Media images provide a constant reminder of the changes that humankind faces.Human hands are responsible for some of these changes whilst others are shaped by nature.For example floods,earthquakes,wars,economic pressures,discrimination and prejudice create upheaval and human uncertainty;leaving a social legacy in which nurses live and work.Likewise,images of nursing are challenged,and changed in the light of high profile media debate about health resources and the quality of nursing care.Such images give cause to question one of the fundamental principles of Nightingale,that‘hospital should do the sick no harm’[1].Given the theme,‘Nurses:A Force for Change e A vital resource for health’it is timely to reflect upon nursing and the policies,politics and planning required for positive change.

Mendelian randomization study to investigate the causal relationship between plasma homocysteine and chronic obstructive pulmonary disease

BACKGROUND:Several observational studies have shown an association between homocysteine(Hcy)levels and chronic obstructive pulmonary disease(COPD),but causal relationships are not clear.Our study aimed to explore the causal relationship between plasma Hcy and COPD by two-sample Mendelian randomization(MR).METHODS:A two-sample MR study was performed to infer the causal link.Genetically predicted plasma Hcy was selected as an instrumental variable(Ⅳ)from published genome-wide association study(GWAS)meta-analyses.COPD with different etiologies was extracted as outcome variables from other GWAS meta-analyses.The main MR analysis was performed using the inversevariance weighted(IVW)method.Additional analyses were further performed using Cochran’s Q-test and MR-Egger regression to evaluate the heterogeneity or horizontal pleiotropy of our findings.RESULTS:MR analysis showed no significant association between plasma Hcy and COPD.The results of the groups were consistent with the sensitivity analysis and repeated analysis,without heterogeneity or horizontal pleiotropy.The IVW results showed COPD hospital admissions(odds ratio[OR]1.06,95%confidence interval[CI]0.91-1.24,P=0.42),asthma/COPD(OR 0.97,95%CI0.89-1.06,P=0.55),COPD-related chronic infection(OR 1.50,95%CI 0.57-3.99,P=0.41),COPDI asthma/interstitial lung disease(ILD)-related pneumonia or pneumonia-derived septicemia(OR 0.93,95%CI 0.86-1.02,P=0.13),and COPD-related respiratory insufficiency(OR 1.00,95%CI 0.7-1.44,P=0.99).CONCLUSION:There is no direct causal relationship between plasma Hcy and COPD in our study.As Hcy is known to have deleterious effects on endothelial function and vascular homeostasis,further studies are needed to investigate whether additional factors mediate the association between Hcy and COPD.